Free Trial
NASDAQ:ALXO

ALX Oncology (ALXO) Stock Price, News & Analysis

ALX Oncology logo
$1.62 +0.14 (+9.46%)
(As of 12/20/2024 05:45 PM ET)

About ALX Oncology Stock (NASDAQ:ALXO)

Key Stats

Today's Range
$1.51
$1.67
50-Day Range
$1.21
$1.84
52-Week Range
$1.19
$17.83
Volume
2.17 million shs
Average Volume
829,609 shs
Market Capitalization
$85.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Moderate Buy

Company Overview

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

ALX Oncology Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
64th Percentile Overall Score

ALXO MarketRank™: 

ALX Oncology scored higher than 64% of companies evaluated by MarketBeat, and ranked 384th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ALX Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ALX Oncology has only been the subject of 3 research reports in the past 90 days.

  • Read more about ALX Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for ALX Oncology are expected to grow in the coming year, from ($2.76) to ($2.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ALX Oncology is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ALX Oncology is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ALX Oncology has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    20.90% of the float of ALX Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    ALX Oncology has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in ALX Oncology has recently decreased by 0.83%, indicating that investor sentiment is improving.
  • Dividend Yield

    ALX Oncology does not currently pay a dividend.

  • Dividend Growth

    ALX Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.90% of the float of ALX Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    ALX Oncology has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in ALX Oncology has recently decreased by 0.83%, indicating that investor sentiment is improving.
  • News Sentiment

    ALX Oncology has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for ALX Oncology this week, compared to 3 articles on an average week.
  • Search Interest

    Only 5 people have searched for ALXO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added ALX Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ALX Oncology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $46,500.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    33.40% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    97.97% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ALX Oncology's insider trading history.
Receive ALXO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter.

ALXO Stock News Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Jefferies Downgrades ALX Oncology Holdings (ALXO)
ALX Oncology to present updated results from Phase 2 ASPEN-06 trial
ALX Oncology Holdings (ALXO) Gets a Hold from LifeSci Capital
See More Headlines

ALXO Stock Analysis - Frequently Asked Questions

ALX Oncology's stock was trading at $14.89 on January 1st, 2024. Since then, ALXO stock has decreased by 89.1% and is now trading at $1.62.
View the best growth stocks for 2024 here
.

ALX Oncology Holdings Inc. (NASDAQ:ALXO) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.01.

ALX Oncology (ALXO) raised $128 million in an IPO on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor acted as the underwriters for the IPO and LifeSci Capital was co-manager.

ALX Oncology's top institutional shareholders include FMR LLC (11.12%), Redmile Group LLC (7.27%), State Street Corp (1.27%) and Privium Fund Management B.V. (0.97%). Insiders that own company stock include Jaume Pons, Sophia Randolph, Jason Lettmann, Peter S Garcia, Shelly Pinto and Rekha Hemrajani.
View institutional ownership trends
.

Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ALX Oncology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/08/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALXO
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$25.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+424.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-160,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.81 per share

Miscellaneous

Free Float
35,127,000
Market Cap
$85.44 million
Optionable
Optionable
Beta
1.04
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:ALXO) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners